alpn-101
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 29, 2019 (NCT03748836)
Timeline
Indications
Mechanism of action
- Inducible T-cell costimulatorINHIBITOR
ICOS inhibitor
CD28 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04835441 | Phase 2 | Jun 22, 2021 | Alpine Immune Sciences |
| NCT04227938 | Phase 1 | Mar 31, 2020 | Alpine Immune Sciences |
| NCT03748836 | Phase 1 | Jan 29, 2019 | Alpine Immune Sciences, Clinical Network Services |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alpine Immune Sciences | For profit | 3 | 3 | 2 | 2019 |
| Clinical Network Services | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1